take-all' event; we all won by this added section of the puzzle.
It is also very important to recognize that the puzzle is far from being complete. In the following sections, I will mention the work of a number of individuals whose observations contributed to, or have yet to be connected with, the important section of the puzzle added by Dr Beutler and colleagues. I will also address a variety of scientific issues not raised by Dr Beutler. The reader is directed to a a rather comprehensive analysis of some of these issues that was published in 1999, 1 which ends with a note in proof following the identification of tlr4 as Lps.
CLONING LPS THE 'HARD' VERSUS THE 'EASY' WAY
Dr Beutler chronicles failed approaches taken by his laboratory to identify Lps or its product prior to his commitment to a positional cloning approach, including his own laboratory's efforts to prepare an antibody that would detect differences in LPS-responsive versus C3H/HeJ cells. (For a wonderful account of another failed effort to make such an antibody, the reader is directed to an article written by Dr James Watson et al. in 1980. 2 ) One of the puzzle pieces that remains missing is the specificity of the antiserum prepared in the mid-1970s by Antonio Coutinho's laboratory which not only distinguished between C3H/HeJ and LPS-responder lymphoid cell types by immunofluorescent staining, but also was central to the identification of the C57BL/10ScCr strain as LPS-unresponsive (e.g. the failure of this reagent to stain cells derived from the C57BL/10ScCr strain prompted Coutinho and colleagues to assess this strain's LPS sen-sitivity 3 ). Given what we now know of the point mutation in tlr4 expressed by C3H/HeJ cells versus the deletion of tlr4 in C57BL/10ScCr cells, 4, 5 one would not conclude that Dr Coutinho's antiserum would be able to detect TLR4, since the point mutation found within the intracytoplasmic domain of the C3H/HeJ TLR4 would not be expected to alter cell surface expression, although this has yet to be demonstrated formally. Possibly, Dr Coutinho's antiserum detected an epitope within the normal TLR4 that is rendered cryptic by a conformational change caused by the C3H/HeJ point mutation or, possibly, an ancillary protein that requires normal TLR4 tertiary structure for its association with TLR4. Alternatively, the expression of the mutated form of TLR4 (or the lack of TLR4 in C57BL/10ScCr mice) may affect the distribution of gangliosides in cell membranes, as has been reported previously in C3H/HeJ cells. 6 Unfortunately, this puzzle piece may be one that remains in someone's pocket or fell under the table.
Dr Beutler is correct in stating that you do not often read about failed experimental approaches. However, during the time prior to Dr Beutler's entrée into positional cloning, several other groups (including our own) attempted to clone Lps using retrovirus-immortalized C3H/HeJ macrophages (GG2EE cells), 7 C3H/HeJ bone marrow macrophages expanded in GM-CSF, or non-immortalized, CSF-dependent, C3H/HeJ macrophage cell lines 8 as 'recipients' for clones derived from various LPS-responsive cDNA libraries. The saga of some (but not all) of these failed experimental approaches has been detailed elsewhere, 1 and I would defy anyone who has used this strategy to refer to this as the 'easy' solution, as suggested by Dr Beutler's account. For example, highly sensitive approaches for the detection of 'gain of function' within a single transfected macrophage were devised. Despite the adequacy and sensitivity of these detection methods, the failure to identify a clone with the capacity to reverse LPS-hyporesponsiveness in C3H/HeJ macrophages after extensive screening led us to conclude that the Lps cDNA was likely to be under-represented within the library, dependent upon the expression of a second gene that was faulty in the C3H/ HeJ strain, or not expressed at sufficiently high levels in situ. Subtractive library approaches using RNA derived from Lps n and Lps d primary macrophages or cell lines were also carried out and, although they failed to identify tlr4, they were successful in identifying genes that are differentially expressed. 9, 10 In retrospect, given the single point mutation nature of the C3H/HeJ tlr4 defect, it is not at all surprising that this gene would not have been detected by subtractive hybridisation approaches. However, had C57BL/10ScCr macrophages been used, rather than C3H/ HeJ macrophages, tlr4 might well have been identified as being expressed differentially! The roles of some of these gene products in endotoxicity have since been identified, while others (e.g. caveolin-1 10 ) remain to be determined. The latter is particularly intriguing since caveolin-1 has been identified as a repressor of signaling in other systems (discussed by Lei and Morrison 10 ), and its potential for interaction with and regulation of TLR4-associated signaling is an exciting possibility. Other failed approaches to the identification of Lps were nonetheless informative because they resulted in the exclusion of various candidate genes as Lps. For example, given the published association of LPS-sensitivity and the effects of interferon (IFN) on LPS sensitivity (including an early publication by Dr Beutler; discussed below), we hypothesized that the defect in C3H/HeJ signaling might be secondary to a mutation within one of the many IFN-α/β genes that were mapped distal to Lps. Specifically, in 1989, Marion Fultz 11 took advantage of the differential LPS sensitivity of the BXH recombinant inbred mice that were originally used to map Lps, and a unique restriction fragment length polymorphism (RFLP) detected only within IFN alleles derived from the C57BL/6 background, to demonstrate unequivocally that Lps and Ifn loci were separated by >13 cM.
However, Anthony Kang, a graduate student in Peter Wong's laboratory, successfully utilized an expression cloning approach to identify a clone from a C3H/HeN cDNA library that restored to primary C3H/HeJ B cells their capacity to respond to LPS. 12 This clone was identified by sequencing as the gene that encodes Ran/TC4, a GTP binding protein that facilitates transport across the nuclear membrane. Moreover, using a C3H/HeJ cDNA library, they identified multiple cDNA clones that each exhibited a point mutation within the 3′ UTR of this gene. The publication of these data was met with various degrees of scepticism; nonetheless, it appeared that Lps might well have been cloned and it seemed appropriate that the work had been initiated in the laboratory of Dr Barnett Sultzer, who had already contributed enormously to the C3H/HeJ portion of the puzzle (reviewed by Vogel et al. 1 ). However, the original report by Kang et al. raised a large number of new questions. Did this point mutation within the 3′ UTR represent a unique molecular mechanism since there was no apparent difference in steadystate Ran/TC4 mRNA levels in C3H/HeJ versus fully LPS-responsive cells? Although the authors claimed in their discussion that this gene mapped to chromosome 4, did it coincide with the position previously ascribed to Lps? Where was the evidence that the point mutation was also expressed in authentic C3H/HeJ DNA (i.e. not just in the clones derived from the library)?. There were simply too many missing puzzle pieces and, clearly, this finding was eclipsed several years later by the strong data supporting the identification of tlr4 as Lps. 4, 13 Nonetheless, Peter Wong's subsequent findings, 14, 15 that the expression of this mutated form of Ran/TC4 in normal mice results in protection from a lethal dose of LPS, as well as the capacity of this clone to inhibit LPS-sensitivity in normal macrophages, suggests that they have identified an altered form of Ran/TC4 whose expression somehow interferes with TLR4-dependent signaling by what appears to be a novel molecular mechanism. Perhaps, the failure of Dr Beutler and colleagues to identify this mutation in the 3′ UTR region of authentic C3H/HeJ DNA (as stated in his Note {43}) is due to the fact that Ran/TC4 is a member of a large family of highly homologous genes and that the primers chosen for sequencing of this 3′ UTR were simply insufficiently selective. Also in fairness to Dr Wong, and contrary to Dr Beutler's dismissal of the chromosome 4 location of Ran, several members of the Ran family of genes have, in fact, been located proximal to Lps on chromosome 4. Perhaps Wong and co-workers' early localization of Ran to chromosome 4 by fluorescent techniques was related to the detection of these other closely related genes. Nonetheless, the original claim that Ran/TC4 is Lps was based on its ability to restore LPS sensitivity in C3H/HeJ B cells, macrophages, and in vivo; independent confirmation of this finding is necessary and, if found, would identify an additional portion of the puzzle not previously appreciated.
THE '(BIZARRE) EXCHANGE OF DATA'
Dr Beutler's recollection of an exchange of information in 1995 omitted several important details. Significantly, in the course of defining the limits of the ~5.5 cM region that contained Lps in our BALB/c congenic Lps d strain, several microsatellite markers were ordered as a result of polymorphisms between BALB/c and C3H/HeJ mice. 16 In addition, we had also just completed studies using crosses of C3H/HeJ mice with mice that carried deletions that surrounded the brown coat color gene, which had been linked to Lps. It was surprising to read in Dr Beutler's paper that he was sceptical of our data, as he asked (and was granted) permission to present the raw data as part of his presentation at a workshop entitled Future of Sepsis Research held at the NIH in August 1995. As stated in his paper, we willingly shared the data with him, along with detailed maps of the region of which he was unaware. 17, 18 As a result, Dr Beutler and colleagues realized that they had misoriented their contig. I think that Dr Beutler would agree that our sharing of this critical information with him saved considerable time in their positional approach, since without it, they would have continued to sequence their contig in the wrong direction.
Also with regard to our novel approach to narrowing the interval that contained Lps, the strategy (detailed in Vogel et al. 19 ), at least conceptually, was remarkably simple: if the chromosome carrying the deletion retained Lps, then a heterozygotic F1 mouse should be identifiable (Lps d x Lps n ), and based on the literature (reviewed in Vogel et al. 1 ), this should result in a mouse that would exhibit intermediate to full responsiveness when challenged with LPS. If the F1 mouse contained the C3H/HeJ Lps d allele in trans with a deletion that encompassed Lps (e.g. Lps d x Lps 0 ), then no response to LPS should be detected. Based on the relatively large number of finelymapped, distinct, brown deletion mutant strains that were available, we expected to be able to narrow the interval that contained Lps in a relatively short time-frame. We began with two distinct brown deletion mutants that spanned the largest regions (~9 cM) of chromosome 4 distal and proximal to the mapped position of Lps. Importantly, in this study, all F1 progeny were coded and genotyped; not until we measured the in vivo response to LPS (TNF production 90 min post-injection), was the code broken. Multiple litters were assayed over a period of many months; virtually all of the sera were assayed in multiple TNF bioassays (with some confirmed by ELISA) to obtain independent measurements. Much to our surprise, when we analyzed the responses of F1 mice derived from such crosses, we found that the Lps d x Lps 0 progeny responded comparably to Lps d x Lps n progeny derived from the same matings, regardless of the deletion mutant tested, as measured by the capacity of these mice to produce bioactive TNF 90 min after a 25 µg challenge of LPS in vivo. Lastly, despite a broadly distributed spread among individual responses, the average F1 TNF levels were nonetheless significantly lower than exhibited by homozygous Lps n controls, consistent with previous findings of co-dominant inheritance in Lps n x Lps d F1 mice (reviewed by Vogel et al. 1 ). By any criteria, this must be acknowledged as an extraordinarily well-controlled series of matings. There were no 'methodological flaws', as claimed in another of Dr Beutler's recent publications, 5 since the goal was to identify a 'some' versus a 'none' response to LPS. In retrospect, it is possible that had we measured the TNF response at 60 min, rather than at 90 min (when levels of TNF in individual mice are at various stages of decline), the spread of individual responses would likely have been tighter. Nonetheless, the data are the data, regardless of whether or not Dr Beutler finds the data to be 'curious, and...[that it has] raised doubts among workers familiar with the genetic basis of endotoxin resistance as we now understand it'. b Granted, it is conceptually difficult to explain these data in the face of early findings in which C3H/HeJ x C57BL/10ScCr F1 mice failed to respond to LPS challenge; 20 however, the genetic backgrounds of the brown deletion mice and C57BL/10ScCr strains are markedly different and, as we proposed in our original publication, several possibilities could account for our findings. Given the existence of >9 TLR genes, one highly plausible explanation is that an alternative TLR molecule expressed by the brown deletion background, but not by C57BL/10ScCr strain, can compensate for a lack of TLR4 in strains in which tlr4 is deleted, such that an intermediate response pattern is observed when the deletion is put in trans with Lps d . We also acknowledged in the discussion section of our paper the possibility that a gene normally contained within the region encompassed by the deletion contributed to the repression of the LPS-inducible TNF response, and that its deletion led to an unmasking of the phenotype. Finally, it is entirely plausible that a gene expressed on the brown deletion background, but not on the C57BL/10ScCr background, encodes a protein that interacts with point-mutated TLR4, rendering it permissive to signaling. Once these pieces of the puzzle are put together with an understanding of the full potential of the various TLRs for their responsiveness to LPS, as well as their potential heteromeric interactions to create new ligand specificities, a more complete picture will undoubtedly emerge. Nonetheless, based on the difference in magnitude of the various F1 mice versus the fully LPSresponsive control mice versus the complete failure of the C3H/HeJ controls to respond in vivo to LPS, our data provided the first compelling evidence that: (i) under certain circumstances, TLR4 is not absolutely necessary to elicit an LPS response in vivo; and (ii) the Lps d allele appears to exert a dominant negative effect in vivo. Certainly, Dr Beutler's in vitro data, published after our in vivo data first came out, support the latter conclusion. 21 Sometimes when we work on a puzzle, the full image is not known; if the section of the puzzle being worked on does not 'fit' with another section, one does not typically discard the pieces.
With regard to Dr Beutler's claim that he was the 'first to grasp the meaning of the mutation', expressed in a patient who exhibited both IL-1 and LPS hyporesponsiveness, we had, by early 1998, established a collaboration with Dr John Gallin's group and had already amassed a significant amount of functional data demonstrating a lack of NF-κB signaling (and subsequently, defective AP-1 translocation, degradation of IκBα, and cytokine gene expression) in peripheral blood monocytes derived from this patient in response to LPS or IL-1, while TNF-induced signaling remained normal. In addition, responsiveness to IL-18 was also found to be impaired, consistent with the finding that IL-18 shares the signaling intermediates with IL-1, TLR2, and TLR4. 22 Since then (i.e. in less than 2 years), we have cloned and/or sequenced from this patient almost all of the genes currently known to be involved in this shared signaling pathway and have yet to identify a polymorphism that accounts for such a profound defect in signaling. However, as Dr Beutler is painfully aware, as evidenced from his 5 year commitment to the cloning of Lps, these things take time. It also suggests the possibility that other, yet-to-be identified molecules participate in the signaling pathway leading to NF-κB translocation.
THE 'ARTEFACT'
Dr Beutler's account concludes that the early reports of TLR2-mediated LPS-induced signaling 22, 23 were artefactual. However, I would argue strongly that had these elegant, unpublished findings not been presented at various meetings in the months preceding Dr Beutler's successful identification of tlr4 as Lps, neither Dr Beutler nor his colleagues who suggested that he look at tlr4 as a candidate gene, would have made the connection when they did between LPS signaling (via TLR2) and the mapping of human tlr4 to a region on human chromosome 9 that had been predicted by others (reviewed in Vogel et al. 1 ) to contain the human Lps homologue. Once again, the data are the data, and although the conclusions drawn from these original transfection studies 22, 23 may have been subject to misinterpretation, they were nonetheless extraordinarily valuable pieces of the puzzle in that they provided a critical intellectual link between LPS signaling and the TLRs.
The underlying reason for this putative 'artefact' is now better understood and is based on the use of LPS preparations that are not free of highly bioactive contaminants, as is typical for commercial preparations of LPS. The most ironic part of this part of the puzzle is that most of us (including Beutler et al. 25 ) have at one time or another attributed an effect to LPS when, in fact, it was due to the action of these remarkably potent contaminants. In fact, Skidmore and Morrison reported in 1975 that certain LPS preparations lost activity on C3H/HeJ cells, but not on C3H/HeN cells, following phenol re-extraction. 26 In the late 1980s, Michele Hogan went on to show that only LPS preparations that were rich in contaminating bacterial proteins, or protein enriched preparations themselves, could induce tumor cytotoxicity 27 or TNF secretion 28 in C3H/HeJ macrophages, in the absence or presence of IFN-γ. Thus, we felt that Dr Beutler's earlier work in which he described LPS-inducibility of TNF gene expression in C3H/HeJ macrophages in the presence of IFN-γ 25 had possibly been misinterpreted since he had used a commercial LPS preparation that was undoubtedly protein-rich. Carl Manthey later developed a repurification procedure that resulted in preparations of LPS that were completely devoid of geneinducing activity on C3H/HeJ macrophages, even at high concentrations and in the presence of IFN-γ. 29, 30 The relationship of this part of the puzzle to TLR-mediated signaling was recently filled in by Matthew Hirschfeld, an MD/PhD student in Janis Weis' laboratory. 31 Using Dr Manthey's protocol, he showed that prior to repurification, commercial preparations of enterobacterial LPS activated both TLR2 and TLR4 transfectants, while repurification of these same commercial LPS preparations eliminated TLR2-mediated signaling. In contrast, synthetic lipid A, or preparations repurified to remove contaminating proteins, stimulated TLR4 transfectants only. 31 Thus, TLR2 transfectants are very sensitive to the contaminants in these commercial preparations. Therefore, the reasons stated by Dr Beutler for this 'system artefact' are conjectural, at best. Given the recent findings of Faure et al. 32 that IFN-γ can up-regulate TLR2 expression, one can now readily understand how Dr Beutler might have come to the mistaken conclusion that IFN-γ 'reversed' the C3H/HeJ defect at the level of TNF production. In toto, the amount of attention paid to this piece of the puzzle is probably largely academic since both TLR2 and TLR4 are apt to be co-ordinately engaged in the signaling processes during a Gram-negative infection, where the host sees both TLR2 and TLR4 ligands.
OTHER MISSING PIECES
As indicated earlier in this commentary, there are many observations that have yet to be explained by Dr Beutler's model that holds as its central tenet that TLR4 is the 'sole transducer' of LPS signaling. How is it that alveolar macrophages derived from C3H/HeJ mice respond to protein-free preparations of LPS, while their peritoneal macrophages are refractory? How does BCG elicit a transient state of LPS responsiveness in C3H/HeJ mice challenged with highly purified LPS preparations when, in fact, their peritoneal macrophages remain refractory in vitro? Why are certain gene subsets differentially expressed in CD14-or Mac-1 knockout macrophages, in the face of apparently normal TLR4 expression? Will LPS be found to utilize alternate TLRs that are expressed in an organ-specific or cell-specific manner? Do heteromeric interactions among TLRs create novel LPS specificities? Is the utilization of TLR4 restricted to enterobacterial LPS/lipid A preparations? How is it that C3H/HeJ macrophages exhibit several measurable responses to purified LPS within the first 2 min of stimulation? Do other membrane-associated, LPS-binding proteins (e.g. CD14, DAF, moesin, etc.) or signaling molecules (e.g. Vav, Rsk, Raf, etc.) physically interact with TLR4? Will the future availability of synthetic non-enterobacterial lipid A structures confirm the recently observed utilization of TLRs other than TLR4? These (many of which are discussed in some detail in Vogel et al. 1 ) and many other puzzle pieces remain to be assembled.
THE 'TAKE HOME' MESSAGE
Given the extraordinary number of puzzle pieces that contributed to the ultimate identification of Lps as tlr4, I was reminded of a passage from Thomas Merton's No Man Is an Island. 33 My successes are not my own. The way to them was prepared by others. The fruit of my labors is not my own:
for I am preparing the way for the achievements of another. Nor are my failures my own. They may spring from the failure of another, but they are also compensated for by another's achievement.
